ResMed is on a mission to cement the lead it’s built while competitor Philips has been out of the CPAP machine-making game. That process of building out its market share for the long-term has recently ...
StockStory.org on MSN
ResMed (RMD): Buy, sell, or hold post Q4 earnings?
Over the past six months, ResMed’s shares (currently trading at $252.56) have posted a disappointing 11.7% loss, well below ...
ResMed's impressive turnaround, driven by margin improvements, innovative products, and GLP-1 drug tailwinds, positions it for significant long-term growth and elevated returns. The company's AirSense ...
ResMed (RMD) is back in focus after reporting higher sales and net income for its second quarter and first half of fiscal 2026, alongside a fresh quarterly dividend declaration of $0.60 per share. See ...
If you are wondering whether ResMed's current share price lines up with its underlying worth, you are not alone. That is exactly what this article will unpack for you. ResMed recently closed at US$259 ...
As it continues to take advantage of the gaping hole left in the CPAP machine market by competitor Philips’ ongoing respiratory recall troubles, ResMed is still fine-tuning its long-term growth ...
Medical equipment maker ResMed will pay $37.5 million to resolve allegations brought by the Department of Justice (DOJ) that it paid kickbacks to durable medical equipment suppliers, sleep labs and ...
ResMed reported $1.28 billion in revenue and $2.43 EPS, driven by strong demand for AirSense 11 and effective cost management. Rising awareness of sleep apnea, aided by wearable devices like Apple ...
SAN DIEGO--(BUSINESS WIRE)--ResMed (NYSE: RMD, ASX: RMD) has launched ResMed MaskSelector, a digital tool to make remote patient mask selection and sizing easier and more effective, helping patients ...
ResMed’s voluntary recall of some of its CPAP mask magnets has now been labeled as Class I by FDA. The agency announced the classification late last week. In November, ResMed began recalling some ...
Shares of ResMed Inc. RMD advanced 1.29% to $255.82 Tuesday, on what proved to be an all-around favorable trading session for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results